SCHEDULE 13G/A: T. Rowe Price Investment Management Discloses 2.6% Passive Stake in NeoGenomics Inc.

T. Rowe Price Investment Management, Inc. has filed an amended Schedule 13G, reporting a 2.6% beneficial ownership stake in NeoGenomics Inc. as of March 31, 2025.

Summary

• T. Rowe Price Investment Management, Inc. (TRPIM) filed an Amendment No. 2 to Schedule 13G, disclosing its beneficial ownership in NeoGenomics Inc.
• As of March 31, 2025, TRPIM beneficially owns 3,317,169 shares of NeoGenomics Inc.'s common stock.
• This ownership represents 2.6% of the total outstanding common stock of NeoGenomics Inc.
• TRPIM holds sole voting power and sole dispositive power over all 3,317,169 shares.
• The filing indicates that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of NeoGenomics Inc.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing disclosing beneficial ownership and does not contain information that would inherently indicate a positive or negative sentiment regarding the issuer's performance or prospects.

Positives

• The document indicates a significant investment by T. Rowe Price Investment Management, Inc., a reputable investment firm, holding 2.6% of NeoGenomics Inc.'s common stock, which may be viewed as a vote of confidence by a major institutional investor.

Negatives

• The document does not contain explicit negative financial or operational information about NeoGenomics Inc.

Risks

• The document, a Schedule 13G filing, does not detail specific risks related to NeoGenomics Inc.'s operations or financial health, as its primary purpose is to disclose beneficial ownership.

Future Outlook

The document, a Schedule 13G filing, does not provide any forward-looking statements or guidance regarding NeoGenomics Inc.'s future outlook.

Management Comments

• T. Rowe Price Investment Management, Inc. certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
• T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

Industry Context

This Schedule 13G filing reflects a routine disclosure of institutional ownership by a major investment management firm, T. Rowe Price Investment Management, Inc., in NeoGenomics Inc., a company in the diagnostics and oncology industry. Such filings are standard regulatory requirements for passive investors holding significant stakes.

Comparison to Industry Standards

• This document, a Schedule 13G, is a disclosure of beneficial ownership and does not contain information suitable for comparison to industry-specific operational or financial benchmarks or specific comparable companies or projects.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership by T. Rowe Price Investment Management, Inc.

Next Steps

• The document does not specify any future actions, events, or milestones for NeoGenomics Inc. related to this ownership disclosure.

Key Dates

Keywords

NeoGenomics Inc, T. Rowe Price Investment Management, Schedule 13G, beneficial ownership, common stock, investment adviser, SEC filing, institutional ownership